Cite

HARVARD Citation

    Maurillo, L. et al. (n.d.). Minimal residual disease as biomarker for optimal biologic dosing of ARA‐C in patients with acute myeloid leukemia. American journal of hematology. 90 (2), pp. 125-131. [Online]. 
  
Back to record